Ketamine as the prototype glutamatergic antidepressan systematic review and meta-analysis of efficacy

Therapeutic Advances in Psychopharmacology

4, 75-99

DOI: 10.1177/2045125313507739

Citation Report

#	Article	IF	Citations
1	Ketamine: repurposing and redefining a multifaceted drug. Drug Discovery Today, 2014, 19, 1848-1854.	3.2	40
2	Multistage drug effects of ketamine in the treatment of major depression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 55-65.	1.8	38
3	Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Therapeutic Advances in Psychopharmacology, 2014, 4, 156-169.	1.2	99
4	Psychoanalytic Psychotherapy in Contemporary Mental Health Services: Current Evidence, Future Role and Challenges. British Journal of Psychotherapy, 2014, 30, 229-242.	0.1	4
5	Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 pilot study. Journal of Psychiatric Research, 2014, 59, 101-107.	1.5	56
6	Ketamine and phencyclidine: the good, the bad and the unexpected. British Journal of Pharmacology, 2015, 172, 4254-4276.	2.7	144
8	Ketamine and other glutamate receptor modulators for depression in adults. The Cochrane Library, 2015, , CD011612.	1.5	105
9	Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. The Cochrane Library, 2015, , CD011611.	1.5	65
10	A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders. Psychology Research and Behavior Management, 2015, 8, 115.	1.3	31
11	Effect of Ketamine, Thiopental and Ketamineâ€“Thiopental Combination during Electroconvulsive Therapy for Depression. Turkish Journal of Anaesthesiology and Reanimation, 2015, 43, 313-317.	0.8	18
12	Ketamine for Posttraumatic Stress Disorderâ€”Reply. JAMA Psychiatry, 2015, 72, 95.	6.0	6
13	Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Research, 2015, 230, 682-688.	1.7	120
14	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. Current Behavioral Neuroscience Reports, 2015, 2, 216-225.	0.6	18
15	Legal highs: staying on top of the flood of novel psychoactive substances. Therapeutic Advances in Psychopharmacology, 2015, 5, 97-132.	1.2	136
16	Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. General Hospital Psychiatry, 2015, 37, 178-184.	1.2	96
17	Ketamine as a promising prototype for a new generation of rapidâ€acting antidepressants. Annals of the New York Academy of Sciences, 2015, 1344, 66-77.	1.8	97
18	Ketamine and suicidal ideation in depression: Jumping the gun?. Pharmacological Research, 2015, 99, 23-35.	3.1	38
19	Association Among Posttraumatic Stress Disorder, Adverse Birth Outcomes, and Domestic Violence. JAMA Psychiatry, 2015, 72, 94.	6.0	3

#	Article	IF	Citations
20	Tianeptine in an experimental medicine model of antidepressant action. Journal of Psychopharmacology, 2015, 29, 582-590.	2.0	6
21	Five potential therapeutic agents as antidepressants: a brief review and future directions. Expert Review of Neurotherapeutics, 2015, 15, 1015-1029.	1.4	8
22	Criticisms of drugs in early development for the treatment of depression: what can be improved?. Expert Opinion on Investigational Drugs, 2015, 24, 445-453.	1.9	12
23	Dual serotonergic signals: a key to understanding paradoxical effects?. Trends in Cognitive Sciences, 2015, 19, 21-26.	4.0	32
24	Mania following ketamine abuse. Neuropsychiatric Disease and Treatment, 2016, 12, 237.	1.0	10
25	Recreational Use of Ketamine and Its Interaction with NMDA Receptors. , 2016, , 672-680.		1
26	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychological Medicine, 2016, 46, 623-635.	2.7	108
27	KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPIDâ€ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2016, 33, 689-697.	2.0	150
28	Placeboâ€controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 2016, 134, 48-56.	2.2	160
29	The Prefrontal Dectin-1/AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-Î²-Glucan from Maitake. Scientific Reports, 2016, 6, 28395.	1.6	11
30	Ketamineâ€™s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies. , 2016, , 99-121.		1
31	In-patient rehabilitation: clinical outcomes and cost implications. BJPsych Bulletin, 2016, 40, 24-28.	0.7	15
32	BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	12
33	Single-dose infusion ketamine and non-ketamine N-methyl-<scp>d</scp>-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 2016, 46, 1459-1472.	2.7	292
34	Two standardized fractions of Gardenia jasminoides Ellis with rapid antidepressant effects are differentially associated with BDNF up-regulation in the hippocampus. Journal of Ethnopharmacology, 2016, 187, 66-73.	2.0	30
35	Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening. Pharmacology Biochemistry and Behavior, 2016, 150-151, 22-30.	1.3	12
36	Ketamine: a novel antidepressant with a fast onset of action?. BJ Psych Advances, 2016, 22, 216-221.	0.5	0
37	Glutamate-Based Drug Discovery for Novel Antidepressants. Expert Opinion on Drug Discovery, 2016, 11, 873-883.	2.5	14

#	Article	IF	Citations
38	The Glutamate mGluR5 Receptor as a Pharmacological Target to Enhance Cognitive Function: Emerging Evidence from Psychosis Models. , 2016, , 731-750.		0
39	KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depression and Anxiety, 2016, 33, 698-710.	2.0	94
40	Early Complete Remitters After Electroconvulsive Therapy. Journal of ECT, 2016, 32, 82-87.	0.3	12
41	Has psychiatry tamed the â€œketamine tiger?â€•Considerations on its use for depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 218-224.	2.5	22
42	Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv124.	1.0	175
43	3â€™-Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. International Journal of Neuropsychopharmacology, 2016, 19, pyv112.	1.0	22
44	Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior. Biological Psychiatry, 2016, 79, 776-786.	0.7	201
45	Hypoestrogenism alters mood: Ketamine reverses depressive-like behavior induced by ovariectomy in rats. Pharmacological Reports, 2016, 68, 109-115.	1.5	14
46	Ketamina asociada a terapia electroconvulsiva en depresiÃ³n resistente al tratamiento en pacientes de edad avanzada: a propÃ³sito de 2 casos. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 125-126.	1.0	0
47	Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain. Therapeutic Advances in Psychopharmacology, 2017, 7, 137-140.	1.2	22
49	Effects of Antenatal Maternal Depressive Symptoms and Socio-Economic Status on Neonatal Brain Development are Modulated by Genetic Risk. Cerebral Cortex, 2017, 27, 3080-3092.	1.6	90
50	Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 539-546.	0.7	7
51	Beyond serotonin: newer antidepressants in the future. Expert Review of Neurotherapeutics, 2017, 17, 777-790.	1.4	20
52	Efficacy and safety of ketamine in bipolar depression: A systematic review. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 104-112.	0.2	12
53	Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neuroscience and Biobehavioral Reviews, 2017, 77, 232-236.	2.9	91
54	Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters, 2017, 649, 147-155.	1.0	137
55	Ketamine associated with electroconvulsive therapy for treatment-resistant depression in the elderly: Two case reports. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 125-126.	0.2	0
56	Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2017, 20, 909-918.	1.0	43

#	Article	IF	Citations
57	Lentinan produces a robust antidepressant-like effect via enhancing the prefrontal Dectin-1/AMPA receptor signaling pathway. Behavioural Brain Research, 2017, 317, 263-271.	1.2	24
58	Effects of chronic<scp>l</scp>-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiatrica, 2017, 29, 72-79.	1.0	55
59	Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities. Neuropsychopharmacology, 2017, 42, 1201-1209.	2.8	57
60	Eficacia y seguridad de la ketamina en depresiÃ³n bipolar: una revisiÃ³n sistemÃ¡tica. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 104-112.	1.0	24
61	Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?. Current Topics in Behavioral Neurosciences, 2018, 38, 137-162.	0.8	17
62	Ketamine nano-delivery based on poly-lactic-co-glycolic acid (PLGA) nanoparticles. Applied Nanoscience (Switzerland), 2018, 8, 655-663.	1.6	5
63	A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatrica, 2018, 30, 307-322.	1.0	68
64	Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies. Neurotoxicity Research, 2018, 33, 474-484.	1.3	51
65	General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms. Anesthesia and Analgesia, 2018, 126, 208-216.	1.1	15
66	Ketamine and depression: a narrative review . Drug Design, Development and Therapy, 2019, Volume 13, 3051-3067.	2.0	149
67	A model of human endogenous retrovirus (HERV) activation in mental health and illness. Medical Hypotheses, 2019, 133, 109404.	0.8	7
68	Interleukin-4 signalling pathway underlies the anxiolytic effect induced by 3-deoxyadenosine. Psychopharmacology, 2019, 236, 2959-2973.	1.5	7
69	Rostral Anterior Cingulate Glutamine/Glutamate Disbalance in Major Depressive Disorder Depends on Symptom Severity. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 1049-1058.	1.1	10
70	Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy. Journal of ECT, 2019, 35, 115-121.	0.3	13
71	Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. , 2019, 199, 58-90.		126
72	Antimicrobial effect and proposed action mechanism of cordycepin against Escherichia coli and Bacillus subtilis. Journal of Microbiology, 2019, 57, 288-297.	1.3	35
73	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. International Journal of Neuropsychopharmacology, 2019, 22, 119-135.	1.0	116
74	Neuronal glutamatergic changes and peripheral markers of cytoskeleton dynamics change synchronically 24â€‰h after sub-anaesthetic dose of ketamine in healthy subjects. Behavioural Brain Research, 2019, 359, 312-319.	1.2	11

#	Article	IF	Citations
75	A review on neuroimaging studies of genetic and environmental influences on early brain development. NeuroImage, 2019, 185, 802-812.	2.1	42
76	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. Molecular Psychiatry, 2020, 25, 2355-2372.	4.1	22
77	Ketamine in the Treatment of Major Depressive Disorder. Journal for Nurse Practitioners, 2020, 16, 228-231.	0.4	3
78	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. International Journal of Neuropsychopharmacology, 2020, 23, 230-256.	1.0	38
79	The use of ketamine to cope with depression and post-traumatic stress disorder: A qualitative analysis of the discourses posted on a popular online forum. American Journal of Drug and Alcohol Abuse, 2020, 46, 613-624.	1.1	7
80	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Advances in Pharmacology, 2020, 89, 163-194.	1.2	8
81	Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine. Pharmacology Biochemistry and Behavior, 2020, 192, 172913.	1.3	22
82	Increased use of ketamine for the treatment of depression: Benefits and concerns. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110060.	2.5	11
83	Advances in novel molecular targets for antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110041.	2.5	11
84	Ketamine in Psychiatric Disorders. , 2021, , 1-44.		0
85	Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology, 2021, 238, 1737-1752.	1.5	18
86	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs, 2021, 35, 527-543.	2.7	74
87	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Library, 2021, 2021, CD011612.	1.5	20
88	Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression. Pharmacological Research, 2021, 171, 105761.	3.1	31
89	Recent advances and challenges in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110403.	2.5	2
90	MCH and Depression. , 2018, , 195-206.		3
91	Efficacy of different doses of ketamine as a bolus in major depressive disorder. Caspian Journal of Internal Medicine, 2018, 9, 220-227.	0.1	2
92	Not So Fast. Journal of Clinical Psychiatry, 2020, 81, .	1.1	6

#	Article	IF	Citations
93	Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder. Indian Journal of Psychiatry, 2021, 63, 483.	0.4	3
95	Dissoziativa. , 2016, , 1-22.		0
96	Dissoziativa. , 2018, , 683-699.		0
97	Exploring the Role of Ketamine in Maintaining the Antidepressant Response. Psychiatric Annals, 2018, 48, 437-446.	0.1	0
98	PHARMACOLOGICAL PROFILE OF DIZOCILPINE (MK-801) ANDÂITS POTENTIAL USE IN ANIMAL MODEL OFÂSCHIZOPHRENIA. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2019, 88, 166-179.	0.2	0
99	Major depressive disorder: Validated treatments and future challenges. World Journal of Clinical Cases, 2021, 9, 9350-9367.	0.3	30
101	Use of ketamine in acute cases of suicidality. Innovations in Clinical Neuroscience, 2015, 12, 29-31.	0.1	6
102	Intranasal Ketamine for the Management of Incidental Pain during Wound Dressing in Cancer Patients: A Pilot Study. Indian Journal of Palliative Care, 2018, 24, 58-60.	1.0	3
103	CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity. Neuropharmacology, 2022, 206, 108936.	2.0	6
104	Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. Biochemical and Biophysical Research Communications, 2022, 594, 46-56.	1.0	11
105	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open, 2022, 8, e19.	0.3	45
108	Ketamine treatment for depression: a review. Discover Mental Health, 2022, 2, 9.	1.0	37
109	Ketamine for suicidality: An umbrella review. British Journal of Clinical Pharmacology, 2022, 88, 3990-4018.	1.1	4
110	Esketamine for Unipolar Major Depression With Psychotic Features. Journal of Clinical Psychopharmacology, 2022, 42, 408-412.	0.7	6
111	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology, 0, 13, .	1.6	2
112	Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial. Frontiers in Psychiatry, 0, 13, .	1.3	0
113	Ketamine in Psychiatric Disorders. , 2022, , 4593-4635.		0
114	Investigations of the Activity of Phenobarbitone in Mice Models of Depression. , 2022, 3, 27-36.		0

#	Article	IF	Citations